Guidelines for heart failure management have been published by the American College of Cardiology and the American Heart Association in 2001. These guidelines recommend the use of angiotensin-converting enzyme inhibitors and β blockers to improve the symptoms and prognosis of heart failure. Despite being advocated as the cornerstone of medical management, these agents remain underutilized. Not only are these drugs underutilized, but titration to dosages with proven beneficial effects is lacking. Simply achieving widespread usage of these agents would have a significant impact on heart failure outcomes.
|Number of pages||9|
|Journal||Current Treatment Options in Cardiovascular Medicine|
|State||Published - Dec 2004|